CRISPR screens identify tumor‐promoting genes conferring melanoma cell plasticity and resistance
Open Access
- 16 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in EMBO Molecular Medicine
- Vol. 13 (5), e13466
- https://doi.org/10.15252/emmm.202013466
Abstract
Most genetic alterations that drive melanoma development and resistance to targeted therapy have been uncovered. In contrast, and despite their increasingly recognized contribution, little is known about the non‐genetic mechanisms that drive these processes. Here, we performed in vivo gain‐of‐function CRISPR screens and identified SMAD3, BIRC3, and SLC9A5 as key actors of BRAFi resistance. We show that their expression levels increase during acquisition of BRAFi resistance and remain high in persister cells and during relapse. The upregulation of the SMAD3 transcriptional activity (SMAD3‐signature) promotes a mesenchymal‐like phenotype and BRAFi resistance by acting as an upstream transcriptional regulator of potent BRAFi‐resistance genes such as EGFR and AXL. This SMAD3‐signature predicts resistance to both current melanoma therapies in different cohorts. Critically, chemical inhibition of SMAD3 may constitute amenable target for melanoma since it efficiently abrogates persister cells survival. Interestingly, decrease of SMAD3 activity can also be reached by inhibiting the Aryl hydrocarbon Receptor (AhR), another druggable transcription factor governing SMAD3 expression level. Our work highlights novel drug vulnerabilities that can be exploited to develop long‐lasting antimelanoma therapies.Funding Information
- Fondation ARC pour la Recherche sur le Cancer
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
This publication has 87 references indexed in Scilit:
- The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domainProceedings of the National Academy of Sciences of the United States of America, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growthThe Journal of Experimental Medicine, 2012
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic ProfilingJournal of Clinical Oncology, 2011
- Senescent cells develop a PARP-1 and nuclear factor-κB-associated secretome (PNAS)Genes & Development, 2011
- A Human Model of Epithelial to Mesenchymal Transition to Monitor Drug Efficacy in Hepatocellular Carcinoma ProgressionMolecular Cancer Therapeutics, 2011
- RNAi-Based Screening Identifies Kinases Interfering with Dioxin-Mediated Up-Regulation of CYP1A1 ActivityPLOS ONE, 2011
- Cancer stem cells versus phenotype‐switching in melanomaPigment Cell & Melanoma Research, 2010
- PLX4032, a selective BRAF V600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF WT melanoma cellsPigment Cell & Melanoma Research, 2010
- MITF: master regulator of melanocyte development and melanoma oncogeneTrends in Molecular Medicine, 2006